The patent for Keytruda, a game-changing immunotherapy medication developed by Merck & Co., is set to expire in 2028. This development potentially allows other pharmaceutical companies to create and market their own versions of the drug. This could increase competition, lower prices, and increase patient access to treatment. However, concerns about availability and quality of generic versions arise. The patent expiration also significantly impacts the pharmaceutical industry and the future of immunotherapy.
Latin America targeted with Chinese malware, says Joint Chiefs chair nominee
Over 1,500 PostgreSQL instances have been infected with cryptocurrency mining malware due to an ongoing JINX-0126 attack campaign. This campaign is an evolution of the
